Nov 19 |
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst
|
Nov 18 |
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference
|
Nov 12 |
Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association’s 2024 Late-Breaking Science Sessions
|
Nov 11 |
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus
|
Nov 8 |
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference
|
Nov 7 |
Rocket Pharmaceuticals GAAP EPS of -$0.71 beats by $0.05
|
Nov 7 |
Rocket Pharmaceuticals: Q3 Earnings Snapshot
|
Nov 7 |
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
|
Nov 7 |
Here's Why We're Watching Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Situation
|
Sep 19 |
Rocket: Danon Disease Treatment Program Should Carry The Tide Until Regulatory Moves
|